Chancellor M B, Erhard M J, Hirsch I H, Stass W E
Department of Urology, Magee Rehabilitation Hospital, Jefferson Medical College, Philadelphia, Pennslyvania.
J Urol. 1994 Jan;151(1):111-3. doi: 10.1016/s0022-5347(17)34884-x.
Terazosin was evaluated in 21 normotensive spinal cord injured patients with autonomic dysreflexia. The patients were followed for 3 months during which the autonomic dysreflexia severity and frequency were evaluated. Autonomic dysreflexia severity mean score was significantly improved when measured at baseline and at 1 week, 1 month and 3 months (10.3 +/- 4.2, 5.08 +/- 2.3, 3.83 +/- 2.5 and 4.5 +/- 1.4, respectively, p < 0.0005). No statistically significant change was seen in erectile function and blood pressure. Three patients complained of fatigue, 1 of whom had the dosage reduced from 5 to 2.5 mg. daily. Terazosin appears to be effective in preventing serious harm from autonomic dysreflexia without erectile function impairment. The effectiveness is significant in the first week and remains for at least 3 months.
对21例患有自主神经反射异常的血压正常的脊髓损伤患者进行了特拉唑嗪评估。对这些患者进行了为期3个月的随访，在此期间评估了自主神经反射异常的严重程度和发作频率。在基线、1周、1个月和3个月时测量，自主神经反射异常严重程度的平均评分有显著改善（分别为10.3±4.2、5.08±2.3、3.83±2.5和4.5±1.4，p<0.0005）。勃起功能和血压未见统计学上的显著变化。3例患者抱怨疲劳，其中1例患者的剂量从每日5毫克减至2.5毫克。特拉唑嗪似乎可有效预防自主神经反射异常造成的严重损害，且不会损害勃起功能。其有效性在第一周显著，且至少持续3个月。
